Regeneron shares slide on mixed trial data for smoker's lung drug

UBS Reiterates Neutral Rating on Regeneron Pharma (REGN)

UBS analyst Trung Huynh reiterated a Neutral rating and $633.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Bottom-line: we view today's interim readout as a small positive for the space, and highlights REGN's potentially underappreciated obesity pipeline. On the heels of... More

RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)

RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $662.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "BOTTOM LINE: In-line ph.II data show potential role of trevogrumab in obesity for better quality weight loss, though rapidly... More

BMO Capital Comments on Regeneron Pharma (REGN): 'COURAGE Data/Obesity License Move REGN Forward'

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $600.00 price target on Regeneron Pharma (NASDAQ: REGN)

The analyst comments "Regeneron licenses GLP-1/GIP receptor agonist, HS-20094, for $80M in upfront fees and $1.9B in milestones. Ph 2 data for HS-20094 looks... More

RBC Capital Downgrades Regeneron Pharma (REGN) to Sector Perform

(Updated - May 30, 2025 12:38 PM EDT)

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharma (NASDAQ: REGN) from Outperform to Sector Perform with a price target of $662.00 (from $943.00).

The analyst commented, "We are downgrading REGN to Sector Perform following disappointing... More

Raymond James Reiterates Market Perform Rating on Regeneron Pharma (REGN)

Raymond James analyst Sean McCutcheon reiterated a Market Perform rating on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Friday, before market open, Regeneron and Sanofi reported that one of the Phase 3 studies for itepekimab (IL-33 mAb) on top of background therapy... More

Guggenheim Reiterates Buy Rating on Regeneron Pharma (REGN)

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $810.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "This morning REGN (and partner SAN.PAR) announced mixed results from the itepekimab (IL-33 mAb) program for COPD in former smokers. AERIFY-1 (n=1,127) met the primary endpoint (21-27% reduction in exacerbations) and AERIFY-2 (n=953) did not (2-12% reduction). The AERIFY-1 results were... More

Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)

Baird analyst Brian Skorney reiterated a Neutral rating and $587.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Incrementally negative on itepekimab results. REGN had caught a bounce over the last few weeks as investor anticipation of these Phase 3 results built... More

BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $800.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "A statistically significant benefit in only one of two AERIFY studies muddies the water for itepekimab in COPD. A statistically significant reduction... More

Morgan Stanley Reiterates Overweight Rating on Regeneron Pharma (REGN)

Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $958.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Looking ahead for the stock we expect the near-term focus to be on progress with HD Eylea, while over the medium term this will place increased focus on the company's mid to late stage pipeline to deliver. Trial efficacy and safety results: (1) Efficacy: Specifically, AERIFY-1 met the primary endpoint of significantly reducing moderate or severe acute exacerbations by... More